CN113476447A - Application of meflonizone in preparation of acute liver injury medicine - Google Patents
Application of meflonizone in preparation of acute liver injury medicine Download PDFInfo
- Publication number
- CN113476447A CN113476447A CN202110777560.8A CN202110777560A CN113476447A CN 113476447 A CN113476447 A CN 113476447A CN 202110777560 A CN202110777560 A CN 202110777560A CN 113476447 A CN113476447 A CN 113476447A
- Authority
- CN
- China
- Prior art keywords
- meflufenidone
- liver injury
- acute liver
- medicament
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Abstract
The invention discloses an application of meflufenidone in preparation of an acute liver injury medicament, wherein the meflufenidone is used as a raw material for preparing the acute liver injury medicament, or the medicament comprises a meflufenidone component. The invention discovers that the meflufenidone has the characteristic of treating acute liver injury, so that the application of the meflufenidone in preparing the acute liver injury medicament provides a new medicament for treating the acute liver injury, and has better market value and clinical application prospect.
Description
Technical Field
The invention relates to the field of medicines, and particularly relates to application of meflonization in preparation of a medicine for treating acute liver injury.
Background
Acute Liver Injury (ALI) is a Liver Injury caused by various causes, and its condition progresses rapidly. Studies have shown that exogenous substances, such as viral infections, abuse of alcohol or drugs, and exposure to toxins, can lead to ALI. The first cause of acute liver injury in China is virus infection, and the second cause is medicine. Because chronic liver injury can cause chronic liver inflammation and fibrosis reaction, the necrotizing cirrhosis caused by ALI is not cured. This not only seriously affects the quality of life of the patient, but also imposes a heavy medical burden on the country. Prevention of acute, chronic plus acute and/or chronic liver injury is therefore of great importance to public health. Liver transplantation is one of the most effective treatments for severe ALI, but statistics indicate that fewer than 10% of patients receiving liver transplantation therapy. At present, the treatment of acute liver failure at home and abroad is very limited, and the death rate is very high. Therefore, finding alternative therapies for ALI is an urgent medical need.
A great deal of research has been carried out worldwide to find effective drugs for the prevention and treatment of ALI, some of which have been used clinically for a long time, but the therapeutic effects of these drugs are still unsatisfactory.
Disclosure of Invention
The invention provides an application of meflofenidone in preparation of an acute liver injury medicament, which is used for solving the technical problem of deficiency of the existing medical field in the treatment of acute liver injury medicaments.
In order to solve the technical problems, the invention adopts the following technical scheme:
an application of meflufenidone in preparing a medicine for treating acute liver injury, wherein the meflufenidone is used as a raw material for preparing the medicine for treating the acute liver injury, or the medicine comprises a meflufenidone component.
Mefenidone is 1- (4- ((3- (4-methylpiperazin-1-yl) propyl) amino) benzyl) -5- (trifluoromethyl) pyridin-2 (1H) -one.
Acute liver injury is manifested by rapid loss and abnormality of hepatocyte function, necrosis and apoptosis of a large number of hepatocytes in liver tissue in patients with or without liver disease.
When the meflufenidone is used for treating acute liver injury, the administration dosage is 5.5-16.5 mg/kg.
Compared with the prior art, the invention has the advantages that:
the invention discovers that the meflufenidone has the characteristic of treating lipopolysaccharide/D-galactosamine and canavalin A induced acute liver injury, so that the application of the meflufenidone in preparing the acute liver injury medicament provides a new medicament for treating the acute liver injury, and has better market value and clinical application prospect.
Drawings
FIG. 1 is a (200-fold) graph of HE staining of liver of each group of mice in a lipopolysaccharide/D-galactosamine induced acute liver injury model;
FIG. 2 is a graph (200-fold) showing HE staining of liver of each group of mice in a concanavalin A-induced acute liver injury model.
Detailed Description
The invention is described in further detail below with reference to the figures and specific examples.
Example 1:
in this example, applying meflufenidone to the preparation of drugs for acute liver injury, the therapeutic effect of meflufenidone will be demonstrated below:
1. experimental methods
(1) Preparing an experimental animal model of lipopolysaccharide/D-galactosamine (LPS/D-GaIN) for inducing Acute Liver Injury (ALI) to observe the curative effect of meflufenidone on ALI:
SPF grade C57BL/6 mice (8-10 weeks old, male, 25-28g weight) 33 in total, were divided into 5 groups, control, model and experimental groups, respectively, and the experimental group was further divided according to the dosage of meflonizone: 50mg/kg, 100mg/kg and 150mg/kg of meflufenidone, wherein each group comprises 5, 9, 5, 7 and 7 respectively. The normal saline or the meflufenidone with different dosages is administered by intragastric administration half an hour before the molding. Injecting 0.3ml of normal saline into the abdominal cavity of each mouse in the control group; model group and Meflufenidone-treated mice were molded by intraperitoneal injection at a dose of 100. mu.g/kg LPS and 700mg/kg D-GaIN. Mice were anesthetized 6h after intraperitoneal injection molding and blood was collected to leave serum, followed by sacrifice of the mice.
(2) Experimental animal models of canavalin a (ConA) induced Acute Liver Injury (ALI) were prepared to observe the efficacy of mefenidone to treat ALI:
SPF grade C57BL/6 mice (8-10 weeks old, male, 25-28g weight) were divided into 5 groups, control, model and experimental groups, and the experimental group was further divided according to the dosage of meflonizone: 50mg/kg, 100mg/kg and 150mg/kg of meflufenidone, wherein each group comprises 4, 8, 6, 5 and 6 respectively. The normal saline or the meflufenidone with different dosages is administered by intragastric administration half an hour before the molding. Injecting 0.3ml of normal saline into the abdominal cavity of each mouse in the control group; model group and meflufenidone-treated mice were post-spheronized for intravenous injection molding at a dose of 15mg/kg ConA. Mice were anesthetized 8h after molding and blood was collected to leave serum, and then the mice were sacrificed.
And (3) separating the mouse livers of the step (1) and the step (2), reserving the left outer leaf for preparing a paraffin section, and placing the remaining liver tissue in a liquid nitrogen tank. Liver functions of mice in each group are detected by a continuous monitoring method, and the liver damage condition is observed by HE staining of paraffin sections.
The LPS/D-GaIN model liver tissue damage scoring standard refers to CARLOS A. and the like, and the semi-quantitative analysis is carried out on the pathological damage of the liver by the method. Grading standard: level 0: little or no evidence of injury; level 1: mild injury, vacuolation of the cytoplasm, focal nuclear compaction; and 2, stage: moderate to severe injury with extensive nuclear compaction, cytoplasmic eosinophilia, and loss of intercellular borders; and 3, level: with severe necrosis of the liver with loss of liver cords, hemorrhage and neutrophil infiltration. Each section was scored by randomly selecting 5 fields of 200 x field, and the average was the sample score value for this example.
2. The statistical method comprises the following steps: all metric data are expressed in ± s, and the comparisons between groups were analyzed using one-way variance (ANOVA): this statistical approach is the most common method in drug field experiments for comparison of differences in efficacy between such groups. After differences between groups were obtained, Turky test was used to further verify the differences within the groups, i.e. whether the differences between the model group and the control group and the differences between the dose-administered groups relative to the model group were statistically significant. Defining two sides p < 0.05 is considered statistically significant.
3. Results of the experiment
3.1HE staining results
The liver of the mouse has wide intercellular boundary deletion, hepatic cord loss and necrosis, hepatic sinus congestion and nuclear contraction after 6 hours after LPS/G-GaIN injury. In mice livers treated with mefenidone, the lesions were significantly reduced, the lesion size was reduced (as shown in figure 1), and the liver damage pathology score was significantly reduced (p < 0.05) compared to the model group. See table 1. The mouse liver showed extensive apoptosis, nuclear compaction and necrosis 8 hours after ConA injury. In the liver of mice treated with mefenidone, the lesions were significantly reduced and the extent of damage was reduced compared to the model group (as shown in figure 2).
TABLE 1 score of liver injury in groups of mice with LPS/D-GaIN induced liver injury
In the table, p < 0.05 compared to control; p < 0.01 compared to control; p < 0.001 compared to control;#compared with the model group, p is less than 0.05;##compared with the model group, p is less than 0.01;###compared with the model group, p is less than 0.001.
3.2 measurement results of blood transaminases of mice in each group
Compared with a control group, the mean value of the aminotransferase in the mice of the LPS/D-GaIN model group is obviously increased compared with the average value of the aminotransferase in the mice of the normal group, and the difference has statistical significance (p is less than 0.001); after 100mg/kg and 150mg/kg of meflonizone, the blood transaminase of mice is obviously reduced, and the difference has statistical significance (p is less than 0.001), which is detailed in table 2-1. Compared with a control group, the mean value of the blood transaminase of the mice in the ConA model group is obviously increased compared with that of the mice in the normal group, and the difference has statistical significance (p is less than 0.001); after 100mg/kg of meflufenidone treatment, the glutamic-pyruvic transaminase of the mice is obviously reduced, the difference has statistical significance (p is less than 0.05), after 150mg/kg of meflufenidone treatment, the glutamic-pyruvic transaminase and the glutamic-oxaloacetic transaminase of the mice are obviously reduced, the difference has statistical significance (p is less than 0.05), and the details are shown in a table 2-2.
TABLE 2-1 serum transaminase levels in various groups of mice with liver damage due to LPS/D-GaIN
In the table, p < 0.05 compared to control; p < 0.01 compared to control; p < 0.001 compared to control;#compared with the model group, p is less than 0.05;##compared with the model group, p is less than 0.01;###compared with the model group, p is less than 0.001.
TABLE 2-2 serum transaminase levels (X. + -. S) in groups of mice with liver damage due to ConA
In the table, p < 0.05 compared to control; p < 0.01 compared to control; p < 0.001 compared to control;#p is less than 0.05 compared with the control group;##p is less than 0.01 compared with the control group;###p is less than 0.001 compared with the control group; .
4. And (4) experimental conclusion: mefenanib can effectively treat mice acute liver injury induced by LPS/D-GaIN and ConA.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above-described embodiments. Modifications and variations that may occur to those skilled in the art without departing from the spirit and scope of the invention are to be considered as within the scope of the invention.
Claims (4)
1. The application of meflufenidone in preparation of drugs for acute liver injury is characterized in that meflufenidone is used as a raw material for preparing drugs for acute liver injury or the drugs comprise a meflufenidone component.
2. The use of meflufenidone in the preparation of a medicament for treating acute liver injury according to claim 1, wherein the meflufenidone is administered at a dose of 5.5-16.5 mg/kg in a human body.
3. The use of meflufenidone for the manufacture of a medicament for treating acute liver injury according to claim 1, wherein meflufenidone is 1- (4- ((3- (4-methylpiperazin-1-yl) propyl) amino) benzyl) -5- (trifluoromethyl) pyridin-2 (1H) -one.
4. Use of meflofenidone according to claim 1 in the manufacture of a medicament for the treatment of acute liver injury characterized by rapid loss and abnormality of hepatocyte function, massive hepatocyte necrosis and apoptosis in liver tissue in patients with or without liver disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110777560.8A CN113476447A (en) | 2021-07-09 | 2021-07-09 | Application of meflonizone in preparation of acute liver injury medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110777560.8A CN113476447A (en) | 2021-07-09 | 2021-07-09 | Application of meflonizone in preparation of acute liver injury medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476447A true CN113476447A (en) | 2021-10-08 |
Family
ID=77937821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110777560.8A Pending CN113476447A (en) | 2021-07-09 | 2021-07-09 | Application of meflonizone in preparation of acute liver injury medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476447A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102149682A (en) * | 2009-05-25 | 2011-08-10 | 中南大学 | Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts |
| CN107663167A (en) * | 2016-10-19 | 2018-02-06 | 广州南新制药有限公司 | 1‑（Substituted benzyl）The crystal formation and preparation method of 5 trifluoromethyl 2 (1H) pyridonium salt hydrochlorates |
| CN108283639A (en) * | 2018-05-03 | 2018-07-17 | 中南大学 | Fluorofenidone is preparing the application in treating acute kidney injury drug |
| CN111494370A (en) * | 2020-03-30 | 2020-08-07 | 中南大学湘雅二医院 | Application of Pyr3 in preparation of liver injury protection medicines |
-
2021
- 2021-07-09 CN CN202110777560.8A patent/CN113476447A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102149682A (en) * | 2009-05-25 | 2011-08-10 | 中南大学 | Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl-2-(1H)-pyridone compounds and their salts |
| CN107663167A (en) * | 2016-10-19 | 2018-02-06 | 广州南新制药有限公司 | 1‑（Substituted benzyl）The crystal formation and preparation method of 5 trifluoromethyl 2 (1H) pyridonium salt hydrochlorates |
| CN108283639A (en) * | 2018-05-03 | 2018-07-17 | 中南大学 | Fluorofenidone is preparing the application in treating acute kidney injury drug |
| CN111494370A (en) * | 2020-03-30 | 2020-08-07 | 中南大学湘雅二医院 | Application of Pyr3 in preparation of liver injury protection medicines |
Non-Patent Citations (4)
| Title |
|---|
| CHEN J，等: "\"Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-( trifluoromethyl) pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy\"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 2019, no. 2, pages 222 - 229, XP085314514, DOI: 10.1016/j.bmcl.2017.07.001 * |
| JIANG Y，等: "\"Mefunidone ameliorates diabetic kidney disease in STZ and db/db mice\"", 《FASEB JOURNAL》, vol. 35, no. 1, pages 1 - 18 * |
| 岳淑雯，等: ""急性肝损伤模型及信号通路研究进展"", 《药学研究》, vol. 38, no. 1, pages 1 - 2 * |
| 杨文君: ""ZHC116的抗炎作用研究"", 《中国博士学位论文全文数据库医药卫生科技辑》, no. 1 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoffmann et al. | Successful treatment of postherpetic neuralgia with oral ketamine | |
| CN101484167A (en) | The use of derviate of pyridone for preventing and treating radioactive injury of lungs | |
| JP6642892B2 (en) | Drugs for pulmonary fibrosis including dimethylamino Micheliolide | |
| RU2396075C2 (en) | Application of n-(2-arylpropionyl) sulphonamides for treating spinal cord injures | |
| CN113476447A (en) | Application of meflonizone in preparation of acute liver injury medicine | |
| CN1943757A (en) | A Chinese traditional medicinal composition for treatment of hemicrania and its preparation method | |
| US8927601B2 (en) | Uses of N-butylidenephthalide in treating a liver injury and improving liver function | |
| KR101407611B1 (en) | Dioscoreae Rhizoma comprising the manufacture of a medicament for the treatment of facial nerve paralysis, and the extract beongbeop | |
| TW201326147A (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
| CN113456636A (en) | Application of flufenidone in preparation of acute liver injury medicine | |
| CN102397341A (en) | Traditional Chinese medicine for treating oxyhepatitis | |
| CN114588164A (en) | Application of remazolin in prevention of perioperative hypothermia and shivering | |
| Lao et al. | The effect of oxycodone on post-operative pain and inflammatory cytokine release in elderly patients undergoing laparoscopic gastrectomy | |
| CN114699410A (en) | Application of cepharanthine in preparing medicine for treating rheumatoid arthritis | |
| CN107308121A (en) | The therapeutic agent of liver regeneration | |
| JP3587851B2 (en) | Use of benzidamine in the treatment of TNF-induced pathologies | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| WO2023109859A1 (en) | Stilbene compound and application thereof in prevention and/or treatment for central nervous system-related diseases | |
| CN115531459B (en) | Application of Jingfeng particles in preparing medicament for preventing or treating myocardial infarction | |
| CN111494602B (en) | Composition for treating acute pancreatitis and application thereof | |
| CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
| CN115154461B (en) | Application of atractylenolide I in preparation of medicine for treating sicca syndrome | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN109106917B (en) | Application of traditional Chinese medicine composition in preparation of acute liver injury medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |